Allegations of price fixing have been made by a United States hospital in a United States class action law suit against Australian health care company CSL and its major competitor Baxter International. The allegations concern price fixing of blood plasma products. According to lawyers for the plaintiffs, Baxter and CSL colluded to restrict supply or prevent oversupply of the products in order to increase prices. The law suit follows a decision by the Federal Trade Commission to oppose CSL’s takeover bid of rival firm Talecris Biotherapeutics. In its report setting out the reasons for the decision to block the merger, the United States competition regulator claimed that CSL, Talecris and Baxter engaged in a range of market fixing actions to deliberately cut the supply of blood plasma products in order to increase prices. Baxter and CSL are the world’s largest makers of blood plasma products.